Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

P-023

Supelco

Phentermine solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C10H15N
Número de CAS:
122-09-8
Peso molecular:
149.23
Número MDL:
MFCD00059195
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329820023
NACRES:
NA.24

grado

certified reference material

Formulario

liquid

Características

Snap-N-Spike®/Snap-N-Shoot®

envase

ampule of 1 mL

fabricante / nombre comercial

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIB (Portugal)

concentración

1.0 mg/mL in methanol

técnicas

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

aplicaciones

clinical testing

Formato

single component solution

temp. de almacenamiento

2-8°C

cadena SMILES

NC(C)(C)CC1=CC=CC=C1

InChI

1S/C10H15N/c1-10(2,11)8-9-6-4-3-5-7-9/h3-7H,8,11H2,1-2H3

Clave InChI

DHHVAGZRUROJKS-UHFFFAOYSA-N

Categorías relacionadas

Descripción general

A Snap-N-Spike® reference solution applicable for use in clinical toxicology or urine drug testing by LC-MS/MS or GC/MS. Phentermine, a phenethylamine analog, is a stimulant and an appetite suppressant. This drug is a constituent of the withdrawn anti-obesity medication fen-phen.

Información legal

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Palabra de señalización

Danger

Clasificaciones de peligro

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Órganos de actuación

Eyes

Código de clase de almacenamiento

3 - Flammable liquids

Clase de riesgo para el agua (WGK)

WGK 1

Punto de inflamabilidad (°F)

49.5 °F - closed cup

Punto de inflamabilidad (°C)

9.7 °C - closed cup

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

High demand likely for prescription weight-control drugs.
Mayo Clinic health letter (English ed.), 30(11), 4-4 (2013-06-26)
Kelly Anne Holes-Lewis et al.
The American journal of the medical sciences, 345(4), 284-288 (2013-03-28)
Obesity is a world-wide epidemic associated with significant morbidity and mortality which costs billions of dollars per year. The associated related conditions are many and include heart disease, stroke, type II diabetes mellitus, sleep apnea and certain types of cancer.
Michael H Davidson et al.
The American journal of cardiology, 111(8), 1131-1138 (2013-02-05)
The aim of this analysis was to evaluate changes in cardiovascular risk factors in obese patients with dyslipidemia and/or hypertension receiving phentermine (PHEN) and topiramate extended-release (TPM ER). In the 56-week, randomized, double-blind, placebo-controlled, multicenter CONQUER trial, PHEN/TPM ER demonstrated
Heidi Collins Fantasia
Nursing for women's health, 17(1), 53-62 (2013-02-13)
Obesity, defined as a body mass index (BMI, kg/m(2) ) >30, is a significant public health problem. It's estimated that 50 percent of the U.S. population will be classified as obese by the year 2030. Due to associated health complications
David H Winslow et al.
Sleep, 35(11), 1529-1539 (2012-11-02)
To evaluate safety and efficacy of phentermine 15 mg plus extended-release topiramate 92 mg for treatment of moderate to severe obstructive sleep apnea (OSA) in obese adults. This phase 2, randomized, double-blind, placebo-controlled study included 2-week screening and 28-week treatment
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico